rs11657479 — TBX21 TBX21 3' UTR Variant

TBX21 3' UTR Variant — T-bet Expression Tuning and the Allergy–Autoimmune Axis

T-bet¹¹ T-bet
T-bet (T-box expressed in T cells) is the master transcription factor that drives naive CD4+ T cells toward Th1 differentiation; it simultaneously represses Th2 commitment by physically inhibiting GATA3 and suppressing IL-4 expression. Encoded by TBX21 on chromosome 17q21.32 is the central switch in adaptive immune polarization. When T-bet levels are high, IFN-γ-producing Th1 responses dominate — well-calibrated for intracellular pathogens but also prone to driving spondyloarthritis and autoimmune inflammation when unchecked. When T-bet activity falls, the Th2 program rises to fill the vacuum, promoting IgE class-switching, eosinophil recruitment, and atopic disease. rs11657479 is a 3' UTR variant in TBX21 (GRCh38 chr17:47745535; c.*169T>C) that sits 169 nucleotides downstream of the TBX21 stop codon. 3' UTR variants at this position can alter mRNA stability, polyadenylation efficiency, or microRNA binding, changing the steady-state amount of T-bet protein produced per transcript — with cascading effects on the Th1/Th2 balance.

The Mechanism

Unlike coding variants that change the T-bet protein sequence, rs11657479 operates at the post-transcriptional level. The 3' UTR of mRNAs is a key regulatory zone where microRNAs²² microRNAs
short non-coding RNA molecules ~22 nucleotides long that bind complementary sequences in 3' UTRs, triggering mRNA degradation or translational repression — one of the most widespread post-transcriptional gene regulation mechanisms and RNA-binding proteins control transcript stability and translation efficiency. A T-to-C change at position c.*169 can disrupt or create miRNA seed sequence matches, altering how aggressively the TBX21 transcript is silenced. The functional outcome is measurable at the protein level: in the Lau et al. 2017 study of ankylosing spondylitis patients, CD8+ T cells from individuals carrying risk alleles at rs11657479 showed increased T-bet expression compared to protective allele carriers. The direction is consistent with the C allele stabilizing TBX21 mRNA or reducing its silencing, resulting in more T-bet protein per cell — a shift toward enhanced Th1 tone.

A large GWAS of protein quantitative trait loci (pQTL) detected a highly significant association between rs11657479-C and decreased circulating IL-22 levels³³ decreased circulating IL-22 levels
IL-22 is a cytokine produced by innate lymphoid cells and Th17/Th22 cells critical for mucosal barrier integrity; its reduction is linked to increased intestinal permeability and epithelial vulnerability. This indicates the rs11657479-C allele has a measurable effect on downstream cytokine levels beyond T-bet expression alone — the immunological consequences radiate through the broader inflammatory cytokine network.

The Evidence

The most direct functional evidence comes from the Lau et al. 2017 study⁴⁴ Lau et al. 2017 study
172 AS patients and 83 healthy controls; T-bet expression measured in NK cells, CD8+ T cells, and CD4+ T cells; SKG mouse TBX21-knockout experiments validated the human data. AS patients carrying risk alleles at rs11657479 showed elevated T-bet in CD8+ T cells, with CD8+ T-bet levels completely distinguishing AS cases from healthy controls. Tbx21-knockout SKG mice showed markedly reduced gut and joint inflammation — fewer IFN-γ- and IL-17-producing CD8+ T cells — establishing TBX21 expression level as causally relevant to spondyloarthritis pathogenesis rather than merely correlated.

Genetic association was confirmed in a Chinese population study⁵⁵ Chinese population study
Li et al. 2024; 363 AS patients and 907 controls; four TBX21 SNPs including rs11657479 genotyped. No overall association was found, but stratified analysis of HLA-B27+ AS patients showed the C allele was significantly associated with susceptibility (allelic OR 1.52, 95% CI 1.09–2.11, p=0.028; dominant model OR 1.60). This HLA-B27 interaction is biologically coherent: HLA-B27 misfolding activates UPR pathways and Th17 responses that synergize with elevated T-bet to amplify spondyloarthritis susceptibility.

A study of acute anterior uveitis⁶⁶ study of acute anterior uveitis
Shan et al. 2023; 420 AAU patients, 918 controls; Chinese population found no significant association between rs11657479 and uveitis risk — consistent with the specificity for AS over other HLA-B27-associated conditions. In the allergy context, direct association data for rs11657479 itself are limited, but the broader TBX21 genetic architecture in allergy is well-established: TBX21 variants forming different LD blocks have been consistently associated with childhood asthma risk, and T-bet expression level is a key determinant of Th1/Th2 balance and IgE class-switching. The C allele's association with higher T-bet and lower IL-22 suggests a phenotype where classical atopic susceptibility is reduced but mucosal barrier and autoinflammatory risk are shifted in the opposite direction — the immunological trade-off at the center of the allergy–autoimmune spectrum.

Practical Actions

The rs11657479 C allele is associated with elevated T-bet expression, which may confer partial protection against IgE-mediated atopic disease while increasing susceptibility to Th1/CD8-driven conditions such as ankylosing spondylitis. For CT heterozygotes and especially CC homozygotes, monitoring for early musculoskeletal inflammatory symptoms — morning stiffness, sacroiliac pain, inflammatory back pain improving with movement rather than rest — is the most actionable implication. The reduced IL-22 pQTL association suggests an additional avenue: supporting gut mucosal barrier integrity, which depends on IL-22 for epithelial renewal and antimicrobial peptide production.

TT homozygotes, lacking both C alleles, carry the lower T-bet expression pattern and the higher Th2 tone associated with allergy susceptibility in the TBX21 locus context. For them, the practical relevance runs toward atopic disease monitoring rather than inflammatory arthritis.

Interactions

rs11657479 sits in a 3' UTR position at TBX21, downstream of the coding sequence. The upstream TBX21 promoter variant rs4794067 (-1993T>C) — which increases transcriptional activity and nuclear protein binding affinity — operates through a distinct regulatory mechanism at the 5' end of TBX21. Carriers of C alleles at both rs4794067 and rs11657479 may have compounded upward shifts in T-bet levels through simultaneous transcriptional enhancement and post-transcriptional stabilization. Other TBX21 variants (rs11650354, rs16947078 haplotype; rs11079788 intron-3; rs2240017 H33Q coding) each operate through independent regulatory mechanisms and collectively define the full range of TBX21 expression variation in the population.